2023-505334-10-01招募中2 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Ke Liu
Scientific
Marengo Therapeutics Inc.
研究点 (11)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
已完成
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years2023-506396-94-00Osivax48
进行中（未招募）
1 期
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple MyelomaRelapsed or refractory Multiple Myeloma (r/r MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003414-12-DEHeidelberg Pharma AG130
招募中
2 期
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma2024-515273-10-00Heidelberg Pharma AG71